Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07146451

6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks

The purpose of this study is to evaluate the neurodevelopment at age 6 of children born to women with preterm prelabor rupture of membranes at 22 to 33 weeks of gestation, after antenatal exposure to nifedipine vs placebo.

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 year–78 month

Sex eligibility

All sexes

Study type

Observational

Primary location

Trousseau University Hospital

Paris, France, 75012

Location status: Recruiting

Location contact

Gilles KAYEM, MD, PHD

CONTACT

[email protected]

01 44 73 51 18 ext. +33

About this study

Preterm prelabor rupture of membranes (PPROM) complicates 3% of pregnancies and accounts for one-third of preterm births. It is a leading cause of neonatal mortality and morbidity and increases the risk of maternal infectious morbidity. In cases of early PPROM (22 to 33 completed weeks' gestation), expectant management is recommended in the absence of labor, chorioamnionitis or fetal distress. Antenatal steroids and antibiotics administration are recommended by international guidelines. However, there is no recommendation regarding tocolysis administration in the setting of PPROM. In theory, reducing uterine contractility should delay delivery and reduce the risks of prematurity and neonatal adverse consequences. Likewise, a prolongation of gestation may allow administering a corticosteroids complete course that is associated with a two-fold reduction of morbidity and mortality. However, tocolysis may prolong fetal exposure to inflammation and be associated with higher risk of materno-fetal infection, potentially associated with neonatal death or long-term sequelae, including cerebral palsy.

The investigators implemented the TOCOPROM randomized clinical trial to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22-33 weeks. However, both short- and long-term outcomes should be taken into account to define the optimal treatment strategy. There are currently no data allowing to evaluate the impact of a short course of nifedipine versus placebo on neurodevelopmental outcomes in school-aged children born after PPROM. Therefore, following-up children born to mothers enrolled in the TOCOPROM trial, through a new study, the TOCOKIDS cohort, is a unique and timely opportunity to advance scientific knowledge and adapt clinical practices in France and worldwide.

The assessment at 6 years of age will consist in:

  • A self-administered parental questionnaire, completed online or on paper
  • Data collected from the health book, in particular the 6-year consultation
  • A short psychological assessment (45 minutes), performed remotely by a psychologist through video conference.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All children born to mothers enrolled in the TOCOPROM trial who consented to participate in the 2-year follow-up and who agreed to be contacted for the 6-year follow-up
  • Alive at 6 years
  • Internet access, including access to a good-quality video-conference system (only for the psychological evaluation)
  • Non opposition of the holders of the exercise of parental authority

Exclusion criteria

  • Major malformations and/or chromosomal aberrations evidenced after birth
  • Impossibility to contact the family
  • Opposition to participate in the follow-up

Treatment and study plan

Self-administered parental questionnaire

Other

A self-administered parental questionnaire, completed online or on paper, to assess different dimension of neurodevelopment

A short psychological assessment performed online

Other

NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales.

Results will be classified as normal, mild delay (between 1 and <2 standard deviation [SD] below the mean) or severe delay (≥2 SD).

Primary outcomes

  1. Cerebral palsy at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Cerebral palsy assessed using the Gross Motor Function Classification System (GMFCS), a five-level classification based on the child's current gross motor abilities, limitations in gross motor function, and need for assistive technology and wheeled mobility.

    Severe/moderate cerebral palsy (GMFCS≥2). Mild cerebral palsy (GMFCS-1).

  2. Developmental Coordination Disorder at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Measured using the Developmental Coordination Disorder Questionnaire - European French (DCDQ-FE), a brief parent questionnaire (15 items) designed to screen for gross and fine motor skills and coordination disorders in children, aged 5 to 15 years.

    Total score=15-56: indication of a risk of DCD or suspected of a risk of DCD. Total score=57-75: probably no DCD.

  3. Language at 6 years of age

    Time frame: Up to 6 months after inclusion.

    Language assessed using the verbal communication subscale (4 items) of the 5-15R scale, covering comprehension, expressive language skills and verbal communication, with an extra question on the impact of language and communication difficulties on daily activities.

    Mean (SD). Reference to cut-off scores in relation to the 90 and 98 percentiles (%).

  4. Behavior at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Behavior assessed using the Strengths and Difficulties Questionnaire (SDQ), a brief behavioral screening questionnaire (25 items), designed to screen for symptoms of hyperactivity inattention, emotional, conduct, and peer problems among 2-17 year olds.

    Mean (SD). Abnormal: >90th percentile. Mildly abnormal: 80-90 percentile.

  5. Executive functions at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Executive functions measured using the Childhood Executive Functioning Inventory (CHEXI), a rating instrument (24 items) for parents that was developed for measuring executive functioning in children age 4-12. It includes four different subscales tapping working memory, planning, regulation and inhibition, combined into two global scales: working memory (working memory and planning subscales) and inhibition (inhibition and regulation subscales).

    Normative data are not yet available. Abnormality will be defined considering a cut-off or deviation compared to the mean score, depending on the literature.

Secondary outcomes

  1. Vital status at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Whether the child is alive or not at years of age.

  2. Neurodevelopmental impairment.

    Time frame: Up to 6 months after inclusion.

    Moderate-to-severe impairment (severe/moderate cerebral palsy, and/or abnormal SDQ score, and/or NEMI-3 ≥2 SD below the mean, and/or blindness, and/or deafness), mild impairment (mildly abnormal scores or mild impairment) vs no neurodevelopmental impairment.

  3. Survival without any neurodevelopmental impairment at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Survival without any neurodevelopmental impairment (as defined in the primary endpoint, and then including also cognitive impairment).

  4. Survival without moderate-to-severe neurodevelopmental impairment at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Survival without moderate-to-severe neurodevelopmental impairment (i.e. severe/moderate cerebral palsy, and/or abnormal SDQ score, and/or NEMI-3 ≥2 SD below the mean, and/or blindness, and/or deafness).

  5. Growth at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Height compulsory examination in the sixth year, reported in the health book.

  6. Growth at 6 years of age

    Time frame: Up to 6 months after inclusion

    Weight. Compulsory examination in the sixth year, reported in the health book

  7. Health at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Arterial pressure. Compulsory examination in the sixth year, reported in the health book.

  8. Health at 6 years of age

    Time frame: Up to 6 months after inclusion

    chronic diseases, compulsory examination in the sixth year, reported in the health book

  9. Health at 6 years of age

    Time frame: Up to 6 months after inclusion

    oral health. Compulsory examination in the sixth year, reported in the health book

  10. Vision at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Visual acuity, any vision problem mentioned. Compulsory examination in the sixth year, reported in the health book.

  11. Hearing at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Hearing test. Compulsory examination in the sixth year, reported in the health book.

  12. Development at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Data reported in the health book during the compulsory examination in the sixth year.

  13. Language at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Language test. Compulsory examination in the sixth year, reported in the health book.

  14. Behaviour at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    Data reported in the health book during the compulsory examination in the sixth year.

  15. Cognition at 6 years of age.

    Time frame: Up to 6 months after inclusion.

    NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales.

    Results will be classified as normal, mild delay (between 1 and <2 standard deviation [SD] below the mean) or severe delay (≥2 SD).

  16. Feasibility of performing an online psychological evaluation.

    Time frame: Up to 6 months after inclusion.

    Acceptability E-Scale (adapted - 3 items), participation and completion rates, technical difficulties.

  17. Parent-reported health and development.

    Time frame: Up to 6 months after inclusion.

    Self-reported. Perceived health and development of the child, parental concerns about health and development, and professional diagnoses of health conditions (e.g., asthma, respiratory problems, etc.).

  18. Parent-reported Health-Related Quality of Life.

    Time frame: Up to 6 months after inclusion.

    PedsQL Short Form - 15 items. All items will be added up and linearly transformed on a scale between 0 and 100, a higher score indicating a better HRQoL. Physical and psychosocial functioning will be further assessed using the corresponding subscales. Poor HRQoL, physical or psychosocial functioning will be defined using thresholds compatible with a severe health condition.

  19. Parent-reported school difficulties

    Time frame: Up to 6 months after inclusion

    Ad-hoc questions

  20. Maternal self-perceived health

    Time frame: Up to 6 months after inclusion

    Minimum European Health Module - 1 item

  21. Maternal mental health

    Time frame: Up to 6 months after inclusion

    PHQ-4 (anxiety and depression) - 4 items

  22. Maternal well-being

    Time frame: Up to 6 months after inclusion

    WHO-5 Well-Being Index - 5 items

  23. Maternal quality of life

    Time frame: Up to 6 months after inclusion

    WHOQOL bref FR - 1 item

Study contacts

Contact information is provided by the study sponsor or research team.

Gilles KAYEM, MD,PhD

CONTACT

[email protected]

01 44 73 51 18 ext. +33

Nelly Briand, PhD

CONTACT

[email protected]

01 44 38 18 62 ext. +33

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

6-year Follow-up of Children Born to Mothers Exposed to Nifedipine vs Placebo After Preterm Prelabor Rupture of Membranes at 22 to 33 Weeks of Gestation

Acronym: TOCOKIDS

Important dates

Study start
2025
Primary completion
2033
Study completion
2034
First posted
Aug 28, 2025
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.